Your session is about to expire
← Back to Search
Radioligand Therapy for Recurrent Prostate Cancer (ROADSTER Trial)
ROADSTER Trial Summary
This trial will test whether adding 177-Lutetium-PSMA to standard salvage brachytherapy improves disease control in men with recurrent prostate cancer.
ROADSTER Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowROADSTER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 26 Patients • NCT02805179ROADSTER Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have severe urinary or digestive side effects from past treatments.My prostate cancer has come back, confirmed by a biopsy.My blood counts are within the required range without recent transfusions.I had radiotherapy for prostate cancer over 2 years ago.I have had targeted radiation therapy to my prostate before.My kidneys work well enough, based on a specific calculation.I can safely undergo high dose rate brachytherapy with general anesthesia.My PET scan shows high PSMA activity in the prostate only.I am not suitable for or have declined a specific cancer treatment procedure.My liver tests are within the normal range.I can safely receive treatment with 177Lu-PSMA.I am currently using hormone therapy.
- Group 1: Lutetium Arm
- Group 2: High Dose Radiation (HDR) arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent is High Dose Radiation safe for those undergoing treatment?
"Taking into account the lack of data to support efficacy, our team at Power assigned High Dose Radiation a safety score of 2."
To what extent is enrollment open for this medical experiment?
"Indeed, clinicaltrials.gov states that this medical research is in search of participants. It was first announced on March 17th 2022 and the most recent update occurred on November 22nd 2021. This trial needs 12 individuals from 1 location to complete its study."
Are there still vacancies available for prospective participants in this experiment?
"Affirmative. The clinicaltrials.gov website reveals that this trial is presently recruiting participants, with the initial listing being published on 17th March 2022 and having been recently updated on 22nd November 2022. A total of 12 people are required to be enrolled at a single medical site."
Share this study with friends
Copy Link
Messenger